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Abstract: Erectile dysfunction (ED) is inability to achieve and
maintain an erection to permit satisfactory sexual activity. Homocys-
teine (Hcys) is a sulfur-containing amino acid synthesized from the
essential amino acid methionine. Experimental models have elucidated
the role of hyperhomocysteinemia (HHcys) as a strong and independent
predictor for atherosclerosis progression and impaired cavernosal per-
fusion.
The aim of this study is to investigate the serum levels of Hcys in our
cohort of patients with ED, to compare these values with these of control
population and to examine Hcys as a predictive marker for those patients
who are beginning to complain mild–moderate ED.
A total of 431 patients were enrolled in the study. The whole cohort
was asked to complete the International Index of Erectile Function
(IIEF) questionnaire. The study population was divided in 3 main
groups: Group A: 145 patients with no ED serving as a control group;
Group B: 145 patients with mild or mild–moderate ED; Group C: 141
patients with moderate or severe ED. Each participant underwent blood
analysis. All patients underwent baseline and dynamic penile Doppler
ultrasonography.
We found in our cohort mean Hcys plasma concentrations signifi-
cantly higher than the cut-off point in both groups B and C (18.6 4.7
and 28.38 7.8, respectively). Mean IIEF score was 27.9 1.39,
19.5 2.6, and 11.1 2.5 for groups A, B, and C, respectively
(P< 0.0001). In the penile Doppler ultrasonography studies, a high
significant inverse correlation was detected between the mean values of
the 10th minute’s peak-systolic velocity (PSV) and Hcys levels for theesco Del Giudice, M gonesi, MD,
ncenzo Gentile, MD, and Ettore De Berardinis, MD
than Doppler studies, as the Hcys increase was present in patients with
mild ED even before abnormal Doppler values.
(Medicine 94(39):e1556)
Abbreviations: BMI = body mass index, ED = erectile
dysfunction, EDV = end-diastolic velocity, EDys = endothelial
dysfunction, FA = folic acid, FPG = fasting plasma glucose, Hcys =
homocysteine, HHcys = hyperhomocysteinemia, MS = methionine
synthetase, MTHFR = 5,10-methylenetetrahydrofolate reductase,
PRL = prolactin, PSV = peak-systolic velocity, RI = resistive index.
INTRODUCTION
P enile erection is a neurovascular phenomenon, whichincludes arterial dilatation, corporal smooth muscle relaxa-
tion, and corporal veno-occlusion.1 Erectile dysfunction (ED) is
inability to achieve and maintain an erection to permit satis-
factory sexual activity and may have a relevant impact on the
quality of life of the patients and their partners.2
The incidence of ED increase with age and its prevalence is
very high, affecting up to 53.4% of men aged 30 to 80 years.3
ED can be a manifestation of peripheral atherosclerosis and a
potential early sign of coronary disease, with which it shares
common risk factors such as obesity, smoking, dyslipidemia,
and metabolic syndrome.4 Several pathological conditions that
affect the blood vessels, such as atherosclerosis, can lead to
vasculogenic ED through the important role that endothelial
cells play in vascular homeostasis.5 Deregulated release of
vasodilatation stimulating factors from endothelium is referred
as to endothelial dysfunction (EDys) which can increase the risk
of vascular events. Next to the traditional risk factors of age,
BMI, and smoking, emerging risk factors have been proposed as
predictors for cardiovascular disease as well as ED.6
Experimental models have elucidated the role of hyperho-
mocysteinemia (HHcys) as a strong and independent predictor
for atherosclerosis progression and impaired cavernosal per-
fusion and these findings seemed to be confirmed by clinical
trials performed on study population which assessed HHcys as a
clinically relevant novel risk factor for ED.7
Homocysteine (Hcys) is a sulfur-containing amino acid
synthesized from the essential amino acid methionine, intro-
duced with diet.8 The main metabolic pathways of Hcys are:
transulfuration that is activated after meals, in the presence of
excess methionine, and remethylation, when there are lown the latest pathway, Hcys is converted
tion catalyzed by the enzyme methionine
se cofactor is vitamin B12, and by the
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enzyme 5,10-methylenetetrahydrofolate reductase (MTHFR),
for which folic acid (FA) is a cofactor.9
HHcys can depend on genetic defects, acquired conditions,
or combination of both. Genetic defects cause a reduction in
activity of the enzymes involved in the remethylation pathway
of Hcys, such as MTHFR, MS. Causes of acquired conditions
include vitamin deficiencies, particularly folates and vitamins
B6 and B12, as well as renal impairment.10
Increased levels of Hcys and consequently decreased
levels of FA were found to be able to inhibit NO-synthase,
which is responsible of nitric oxide (NO) production, one of the
most important vasodilatation mediator, whose deficiency plays
an important role in the pathogenesis of EDys and ED.11
The aim of this study is to investigate the serum levels of
Hcys in our cohort of patients with ED, to compare these values
Giovannone et alwith a control population and to examine Hcys as a predictive
marker for those patients who are beginning to complain mild–
moderate ED.
MATERIALS AND METHODS
Between January 2012 and November 2014, 359 patients
affected by ED and 145 men serving as control group with an
average age of 57.4 years (range: 41–70), were enrolled to this
single-centre trial in order to assess the role of Hcys as a
predictor and potential risk factor for ED.
All participants have been enrolled from our Andrology
clinic at the Department of Gynecological-Obstetric Sciences
and Urological Sciences, ‘‘Sapienza’’ Rome University.
In all patients, we evaluated body mass index (BMI) score,
hypertension, smoking attitude, and physical activity.
Each participant underwent blood analysis, which included
lipid panel (total cholesterol, LDL, HDL, triglycerides), fasting
plasma glucose (FPG), Hcys, B12 vitamin, FA, total testoster-
one, LH, FSH, prolactine (PRL), and TSH. Venous blood
samples were obtained in the morning after overnight fasting
and were processed within 4 hours in order to prevent a
temperature and time dependent increase in plasma Hcys.12
Blood values were obtained by using chemiluminescent and
radioimmunoassays (RIA) methods.
In particular, plasmatic levels of Hcys were measured by
using immunodiagnostic method (ELISA) and considering a
reference range of 4.3 to 12mmol/L. Levels >12mmol/L were
used as a cut-off point to assess the risk for the different groups.
Furthermore, all patients underwent baseline and dynamic
penile Doppler ultrasonography using a 7.5–13MHz high-
frequency ultrasound probe. Patients were examined and the
cavernous arteries were studied at baseline conditions after
tactile stimulation and then following intracorporal injection
of 5 to 20mg of alprostadil.
Vascular flow parameters were registered at baseline and
again at 5, 10, and 20minutes postinjection. Patients were
assessed with the penis aimed onto the abdomen and the probe
was placed on the ventral penile surface.
Doppler examinations were performed by a single operator
to minimize possible variability and normal response was
defined by a peak-systolic velocity (PSV) more than 30 cm/
second, end-diastolic velocity (EDV) under 3 cm/second and
resistive index [RI¼ (PSVEDV)/PSV] more than 0.8.
Diagnosis criteria for ED included arterial insufficiency
(PSV< 30 cm/second, EDV 3 cm/second), veno-occlusive
dysfunction (EDV> 3 cm/second, PSV 30 cm/second,
RI< 0.8), and mixed vascular disorder (PSV< 30 cm/second,
EDV> 3 cm/second, RI< 0.8).13
2 | www.md-journal.comThe whole cohort was asked to complete the International
Index of Erectile Function (IIEF) questionnaire that is the self-
administered IIEF based on 15 questions to evaluate ED. We
explored questions 1, 2, 3, 4, 5 about erectile function and
question 15 on personal confidence with a total score in the
range between 6 and 30.
The exclusion criteria were diabetes and metabolic syn-
drome, coronary artery disease, stroke, and neurological dis-
eases (Parkinson’s disease, Alzheimer disease, amyotrophic
lateral sclerosis, etc.), major psychiatric disorders, hypogonad-
ism, and other hormonal diseases (measured through total serum
testosterone, LH, PRL, and TSH).
We have also excluded patients with a history of alcohol-
ism and consumers of illicit drugs, because these may lead to a
chronic reduction of folate levels and vitamins of Group B.
Taking into account the aforementioned criteria, 73 patients
were excluded.
Therefore, according to our criteria, the study population
was divided in 3 main groups. In Group A, 145 patients with no
ED (score 26) were included and used as a control group, in
Group B, further 145 patients with mild or mild–moderate ED
(score 17 and <26) and in Group C 141 patients with
moderate or severe ED (score <17).14
All the patients from the control group were healthy men
who voluntarily decided to participate to the study.
The Ethical Committee of Department of Gynecological-
Obstetric Sciences and Urological Sciences, ‘‘Sapienza’’ Rome
University approved the study protocol. The study was con-
ducted in line with European Urology and Good Clinical
Practice guidelines, with ethical principles laid down in the
latest version of the Declaration of Helsinki. Every patient
signed an informed consent to participate in the study.
Statistical calculations were performed with MedCalc
9.2.0.1 (MedCalc Software, Ostend, Belgium). Hcys plasma
levels were compared between groups by the Mann–WhitneyU
test. Descriptive analysis was based on mean values with range
in case of quantitative variables and on frequencies and per-
centages in case of ordinal and categorical factors. Differences
between groups were accordingly based on Kruskall–Wallis
test or the Chi-square test.
The Spearman correlation was used to evaluate the associ-
ation of Hcys levels with IIEF domain scores and PSVs.
Logistic regression was used to evaluate the combined predic-
tive effect of the risk factors for severe ED. We performed a
backward selection procedure with a removal criterion of
P> 0.10 based on the likelihood ratio test. Model calibration
was measured by the Hosmer–Lemeshow goodness of fit test.
Statistical significance was defined as P 0.05.
RESULTS
Clinical data and fasting laboratory findings detected in the
3 different groups are summarized in Table 1. Patients with ED
in Groups B and C were on average older when compared to the
control group (57.8 4.1 and 58.9 7.2 vs. 55.3 3.5).
The patients complaining any grade of ED were likely to
be active smokers (37.8% and 41.2% for Groups B and C,
respectively, vs. 28.3% for Group A).
Statistically significant differences were detected in BMI,
serum levels of FPG, TSH, FSH, and LH while no significant
differences were detected in prevalence of hypertension, triglycer-
ides, total cholesterol, LDL, HDL, PRL, and total testosterone.
Medicine  Volume 94, Number 39, October 2015Mean plasma levels of Hcys were significantly different in
the cohort showing increasing values in the groups and the
highest levels in patients with severe ED (Figure 1).
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1.35; P¼ 0.0001). The Hosmer–Lemeshow statistic was 5.2
TABLE 1. Participant Clinical Data and Laboratory Findings
Group A (n¼ 145)—Control Group B (n¼ 145) Group C (n¼ 141) P-Value
Age (years) 55.3 3.5 57.8 4.1 58.9 7.2 0.001
BMI (kg/m2) 24.7 2.2 25.3 1.6 25.1 4.1 0.008
Hypertension (%) 12.4% 13.8% 12.1% 0.8
Smoking (%) 28.3%

37.9% 41.1%

0.03

Hcys (mmol/L) 9.55 3.69 18.6 4.7 28.38 7.8 0.0001
Folic Acid (ng/ml) 9.7 3.6 7.6 4.3 6.8 4.1 0.0001
B12 (pg/ml) 428 63 385 93 368 87 0.0001
FPG (mg/dl) 86.3 8.7 88.4 7.9 90.1 9.6 0.03
Triglycerides (mg/dl) 139.3 54.3 143.8 67.1 141.5 41.2 0.5
Total cholesterol (mg/dl) 163.4 28.1 169.1 26.3 165.9 31.2 0.07
LDL (mg/dl) 109.5 34.7 117.3 31.1 112.6 29.7 0.4
HDL (mg/dl) 40.6 9.3 39.5 8.6 41.1 9.1 0.3
TSH (mU/ml) 1.8 0.4 1.6 0.5 1.9 0.4 0.002
FSH (mIU/ml) 3.58 1.19 3.47 1.23 4.09 1.03 0.0001
LH (mIU/ml) 4.13 1.22 4.92 2.66 3.86 1.88 0.0001
PRL (ng/ml) 8.3 3.7 9.2 3.1 8.9 4.2 0.4
Total testosterone (ng/ml) 4.1 1.3 4.0 1.7 3.9 1.4 0.2
IIEF score 27.9 1.1 19.5 2.6 11.1 2.5 0.0001
Values are expressed as meanSD. BMI¼ body mass index; Hcys¼ homocysteine; FPG¼ fasting plasma glucose; LDL¼ low density
hor
on.
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found in our cohort mean Hcys plasma concentrations steady
higher than the cut-off point in both groups B and C (18.6 4.7
and 28.38 7.8, respectively).
Mean IIEF score was 27.9 1.39, 19.5 2.6, and
11.1 2.5 for Groups A, B, and C, respectively (P< 0.0001).
Mean plasma Hcys levels were negatively correlated with
IIEF domain scores for both Groups B (rs¼0.37; P¼ 0.0001)
and C (rs¼0.51; P¼ 0.0001), while in the control group we
found no significant correlation (rs¼0.05; P¼ 0.52)
(Figure 2).
Penile Doppler ultrasonography results detected in the 3
groups are summarized in Table 2. A relevant gap between the
lipoprotein; HDL¼ high density lipoprotein; TSH¼ thyroid-stimulating
PRL¼ prolactin hormone; IIEF¼ International Index of Erectile Functi
denotes statistically significant difference.PSV values in all groups was found (69.2 vs. 61.3 vs. 51.6 at
5 minutes; 65.3 vs. 55.9 vs. 41.2 at 10 minutes; 58.4 vs. 50.4 vs.
38.6 at 20 minutes; Figure 3A) and also between EDV
FIGURE 1. Differences in plasma concentrations of Homocysteine
among the 3 groups.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.parameters (3.8 vs. 5.9 vs. 6.3 at 5 minutes; 2.9 vs. 4.2 vs.
5.1 at 10 minutes; 3.2 vs. 3.8 vs. 4.5 at 20 minutes; Figure 3B).
A high significant inverse correlation was detected
between the mean values of the 10th minute’s PSV and Hcys
levels for the Group B (rs¼0.16; P¼ 0.04) and C
(rs¼0.49; P¼ 0.0001) (Figure 4).
By logistic regression considering age, BMI, arterial hy-
pertension, smoking, and Hcys as independent variables, the
only significant variables were age (OR¼ 1.03, 95% CI: 1.01–
1.15; P¼ 0.0001) and Hcys levels (OR¼ 0.86, 95% CI: 1.23–
mone; FSH¼ follicle-stimulating hormone; LH¼ luteinizing hormone;(P¼ 0.4), thus, showing no evidence of poor calibration of the
logistic regression model.
DISCUSSION
ED, the second most common sexual disorder after pre-
mature ejaculation, has a significant impact on the quality of life
of men and their partners2 and its incidence increase with age
and is connected with several comorbidities.3
Vascular, hormonal, lifestyle, aging, neurologic, and
psychological factors all play a role in the etiology of
ED.15 Several associated metabolic imbalance contribute to
the pathogenesis of EDys through a decreased vascular NO
bioavailability, impaired vasodilatation, enhanced inflam-
mation, and oxidative stress with proliferation of smooth
muscle cells.16 Cavernous endothelial cell dysfunction is
considered one of the most important pathological change
in vasculogenic ED.17
Hcys has been known as an independent risk factor for
vascular disease since 1999, when ‘‘The Rotterdam Study’’
evaluated the association of myocardial infarction and stroke
with elevated levels of Hcys. Patients with HHcys had an odds
ratio of 2.43 and 2.53 for myocardial infarction and stroke,
respectively.18 Similar findings were obtained by Rasouli et al
who indicated that the presence of increased Hcys levels
www.md-journal.com | 3
FIGURE 2. Spearman correlation coefficient (rs) and linear regression line between IIEF domain scores and homocysteine plasma levels in
Giovannone et al Medicine  Volume 94, Number 39, October 2015(>12mmol/L) strongly and independently predict progression
of coronary plaque burden.8
Based on the association of Hcys with cardiac and vascular
events, HHcys was introduced as possible mechanism in the
pathogenesis of ED.
Khan et al showed the correlation between EDys and ED in
experimental models in 1999. This work studied the contri-
bution of free radicals production on ED in the corpora caver-
nosum of rabbits. This study highlighted how HHcys was able to
induce an impaired cavernosal smooth muscle relaxation due to
his capacity to inhibit NO-synthase.19
Groups A, B, and C, and overall population.Elevated levels of Hcys can be reasonably included in a
group of emerging risk factors involved in the pathogenesis of
EDys that can ubiquitously affect the vascular system.
TABLE 2. Penile Doppler Ultrasonography Results in Groups A, B
Mean HcysSD IIEF Score
Group A, n¼ 145 9.55 3.69 27.9 1.1 PSV
EDV
RI
Group B, n¼ 145 18.6 4.7 19.5 2.7 PSV
EDV
RI
Group C, n¼ 141 28.38 7.8 11.1 2.5 PSV
EDV
RI
EDV¼ end-diastolic velocity; Hcys¼ homocysteine; IIEF¼ International
index; SD¼ standard deviation.
4 | www.md-journal.comHcys is a precursor of hydrogen sulfide (H2S), a vasodi-
lator that has an anti-inflammatory, anti-apoptotic, and anti-
oxidant properties.20
The role of Hcys in the EDys is due to a decrease of H2S, a
novel mediator in cardiovascular homeostasis, and also to a
decrease of NO synthesis through an increase reactive oxygen
species (ROS) levels.21
In 2006, Demir et al studied the role of elevated plasma
levels of Hcys in a cohort of 31 nondiabetic patients; this
experience represented the first trial who detected on a
study-based population, a significant association between
HHcys and ED. In particular, the chance of developing ED
was associated for the 80% in the cut-off point of patients who
presented plasmatic levels of Hcys greater than 12.1mmol/L;
, and C
0minute 5minutes 10minutes 20minutes
24.2 69.2 65.3 58.4
1.2 3.8 2.9 3.2
0.9 0.9 0.9 0.9
14.8 61.3 55.9 50.4
1.8 5.9 4.2 3.8
0.9 0.8 0.9 0.9
11.9 51.6 41.2 38.6
2.1 6.3 5.1 1.2
0.8 0.9 0.9 0.9
Index of Erectile Function; PSV¼ peak-systolic velocity; RI¼ resistive
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
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Medicine  Volume 94, Number 39, October 2015 Hyperhomocysteinemia and Erectile Dysfunctionmoreover, in those patients with HHcys was statistically showed
a significant association with impaired flow-mediated vasodi-
latation and vascular abnormalities detected via penile Doppler
ultrasound.7
In another study confirming the role of HHcys as a risk
factor for ED, Lombardo et al showed that the mutation of the
MTHFR gene is a genetic condition that can independently lead
FIGURE 3. (A) Mean peak systolic velocity (cm/second) detected
ultrasonography; (B) mean end diastolic velocity (cm/second) dete
ultrasonography.to HHcys. In this cohort of patients, all the participants were
treated with vitamin B6 and FA therapy revealing an interesting
improvement in the IIEF domain scores after the treatment as
FIGURE 4. Spearman correlation coefficient (rs) and linear regression
levels in Groups A, B, and C, and overall population.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.well as a significant improvement between the values of Hcys at
baseline and at the end of the study.9
As already reported in literature,7 our study provides
additional evidence that Hcys levels are elevated in the group
of patients who complained a severe grade of disease (IIEF
score< 17). A biochemical association between the Hcys levels
and ED was also revealed by penile Doppler ultrasound studies,
the 3 different groups at 00, 50, 100, and 200 in penile Doppler
d in the 3 different groups at 00, 50, 100, and 200 in penile Dopplerwhich demonstrated the severity of the disease in patients of
Group C. More interesting, our experience revealed a moderate
but steady increasing of the levels of Hcys in those patients
line between peak systolic value (PSV) and homocysteine plasma
www.md-journal.com | 5
(Group B) who were beginning to complain a mild or mild–
moderate ED (IIEF score17 and<26). This establishes a dose
dependent association between Hcys and ED. Another import-
ant aspect of our study is that we showed that Hcys was an
earlier predictor of ED than Doppler studies, as the Hcys
elevation was present in patients with mild ED before abnormal
Doppler values. This is remarkable in Group B where, even with
normal Doppler ultrasound examination, Hcys is already elev-
ated and higher than 12mmol/L, considered as maximum
reference level.
The main limitations of this study include the single-center
nature of the report that may have an impact on its external
validation, and the single measurement of the Hcys. A series of
comprehensive blinded validation studies are warranted to
confirm the utility of this biomarker in the clinical setting.
In conclusion, Hcys plasma levels could potentially be
monitored as an early marker of ED prediction and could be
used to identify those patients who may go on to develop severe
ED. According to these findings, Hcys could be proposed as a
Giovannone et alnovel biomarker in the diagnosis of ED and the correction of
Hcys plasma levels, may represent a future target for monitoring
therapy.
CONCLUSIONS
HHcys correlates with ED onset and its plasma levelscorrelate with ED grade of severity. Considering our trial
results, in a next future, Hcys could be used as an early predictor
of ED development.
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